macular degeneration

A new analysis shows huge variation in mutations for induced pluripotent stem cells, including some changes that can severely limit their ability to transform into other kinds of cells.

Age-related macular degeneration is the most common cause of vision loss in adults over age 50, but there are few treatments available. Researchers are now developing promising stem cell therapies to treat the disease.

Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?

Scientists identify a new target for treating age-related eye diseases

Roche's faricimab injected every 16 weeks proves non-inferior to aflibercept injected every eight weeks in patients with “wet” age-related macular degeneration